Here we report a retrospective analysis of a consecutive Swiss population-based ns-NSCLC cohort, subjected to NGS analysis at the time of diagnosis, focusing especially on stage I-III or stage I-II KRAS mutant patients. Here, KRAS is linked to non-small cell lung carcinoma.